CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023

“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report gives comprehensive insight into multiple clinical and non-clinical issues related to emergence and development of global CD Antigen cancer therapy market. CD Antigens have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. CD antigens have been present in disguise since the efforts began to develop therapeutic monoclonal antibodies in 1970s. CD antigens are the basis on which monoclonal antibodies were discovered. Although the potential of antibodies was well understood but it required a series of discoveries to find out that specific antibodies are capable of targeting one unique molecular site of the cancer cells.

“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report highlights:
• Market Opportunity Assessment: More than US$ 60 Billion by 2023
• Clinical & Patent Insight on 17 Commercialize CD Antigen Drugs
• Clinical & Licensing Insight on 184 CD Antigens in Clinical Pipeline
• Dosage & Price Analysis on Key Drugs
• Mechanism of CD Antigen Cancer Therapeutics
• Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50 Drugs
• Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Table of Contents

1. Introduction to CD Antigen Based Cancer Therapeutics
1.1 Prologue to CD Antigens
1.2 Background: Discovering CD Antigens in Cancer Therapy
1.3 Historical Aspects of CD Antigen Based Cancer Therapeutics

2. Significance of CD Antigens: Normal Cells versus Cancer Cells
2.1 CD Antigens in Normal Cells
2.2 CD Antigens in Cancer

3. Working Mechanism of CD Antigen Based Cancer Therapeutics

4. Commercial Cancer Therapeutics Based on CD Antigens
4.1 Monoclonal Antibodies
4.2 Antibody Drug Conjugates
4.3 Bispecific Antibodies

5. Recent Commercial Trends in CD Antigen Based Cancer Therapeutics
5.1 CAR-T Cell Therapy
5.2 Aptamers
5.3 Immunoconjugates
5.3.1 Radio Immunoconjugate
5.3.2 Toxin Immunoconjugate
5.4 Novel CD Antigen Based Antibodies
5.4.1 Bispecific T-Cell Engager Antibody (BiTEs)
5.4.2 DART and TandAb

6. Major CD Antigens as Targets for Cancer Therapy
6.1 CD20
6.2 CD19
6.3 CD137
6.4 CD38
6.5 CD70
6.6 CD22
6.7 CD30
6.8 CD33
6.9 CD37


7. Major CD Antigens as Cancer Diagnostic Agents
7.1 CD20
7.2 CD5
7.3 CD56
7.4 CD66e
7.5 CD15
7.6 CD30
7.7 CD3

8. Major CD Antigens in Cancer Research
8.1 CD34
8.2 CD10
8.3 CD26
8.4 CD117
8.5 CD44
8.6 CD57

9. Global CD Antigen Based Therapeutics Market Overview
9.1 Market Progression
9.2 Current Market Scenario
9.3 Global CD Antigen Based Cancer Therapeutics Market Trends
9.4 Global Cancer CD Antigen Inhibitors Pipeline Overview

10. Price & Dosage Analysis of Major CD Antigen Based Cancer Therapies
10.1 Rituximab (CD20)
10.2 Ofatumumab (CD20)
10.3 Obinutuzumab (CD20)
10.4 Daratumumab (CD38)
10.5 Brentuximab Vedotin (CD30)
10.6 Gemtuzumab Ozogamicin (CD33)
10.7 Inotuzumab Ozogamicin (CD22)
10.8 Ibritumomab Tiuxetan (CD20)
10.9 Blinatumomab (CD19, CD3)
10.10 Tisagenlecleucel (CD19)

11. Marketed Cancer CD Antigen Inhibitors Clinical & Patent Insight
11.1 Rituximab (MabThera & Rituxan)
11.2 Obinutuzumab (Gazyva & Gazyvaro)
11.3 Ibritumomab Tiuxetan (Zevalin & Zevamab)
11.4 Rituximab Biosimilar (AcellBia & USMAL)
11.5 Rituximab Biosimilar (Reditux & Tidecron)
11.6 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima & Tuxella)
11.7 Rituximab Biosimilar (Novex)
11.8 Rituximab Biosimilar (RituxiRel, Toritz & Toritz RA)
11.9 Rituximab Biosimilar (Maball)
11.10 Rituximab Biosimilar (Kikuzubam)
11.11 Rituximab Biosimilar (Mabtas)
11.12 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat & Remniq)
11.13 Avelumab (BAVENCIO)
11.14 Pembrolizumab (Keytruda)
11.15 Atezolizumab (TECENTRIQ)
11.16 Durvalumab (Imfinzi)
11.17 Rituximab Biosimilar (Zytux)

12. Global CD Antigen Cancer Therapy Market Dynamics
12.1 Market Growth Drivers
12.1.1 Large Patient Base
12.1.2 Unmet Medical Need
12.1.3 Better Safety Profile
12.1.4 Accelerated Research & Development: Newly Identified CD Antigens in Cancer
12.1.5 Acquiring Major Share of the Modern Cancer Therapy Market
12.1.6 Strong Clinical Pipeline
12.2 CD Antigen Market Challenges
12.2.1 High Prices of CD Antigen Based Cancer Therapeutics
12.2.2 Difficulties in Differentiating CD Target on Cancer Cells
12.2.3 High Production Cost Due to Complex Structure

13. Global CD Antigens Cancer Therapy Market Future Forecast

14. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
14.1 Research
14.2 Preclinical
14.3 Phase-I

15. Cancer CD3 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
15.1 Preclinical
15.2 Phase-I
15.3 Phase-II

16. Cancer CD4 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
16.1 Phase-I

17. Cancer CD7 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
17.1 Preclinical

18. Cancer CD19 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
18.1 Phase-I
18.2 Phase-I/II
18.3 Phase-II
18.4 Phase-III

19. Cancer CD20 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
19.1 Unknown
19.2 Research
19.3 Preclinical
19.4 Clinical
19.5 Phase-I
19.6 Phase-I/II
19.7 Phase-II
19.8 Phase-III
19.9 Registered

20. Cancer CD22 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
20.1 Preclinical
20.2 Phase-III
20.3 Registered

21. Cancer CD 26 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
21.1 Preclinical
21.2 Phase-I/II

22. Cancer CD27 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
22.1 Research
22.2 Preclinical
22.3 Phase-II

23. Cancer CD30 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
23.1 Phase-I

24. Cancer CD33 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
24.1 Phase-I
24.2 Phase-I/II

25. Cancer CD38 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
25.1 Research
25.2 Preclinical
25.3 Phase-I/II
25.4 Phase-III

26. Cancer CD44 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
26.1 Preclinical
26.2 Phase-I

27. Cancer CD45 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
27.1 Phase-III

28. Cancer CD46 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
28.1 Research

29. Cancer CD 47 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
29.1 Research
29.2 Preclinical
29.3 Phase-I
29.4 Phase-I/II
30. Cancer CD52 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
30.1 Research
30.2 Preclinical

31. Cancer CD55 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
31.1 Preclinical
31.2 Phase-II

32. Cancer CD56 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
32.1 Phase-II

33. Cancer CD66 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
33.1 Phase-I

34. Cancer CD70 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
34.1 Phase-II


35. Cancer CD71 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
35.1 Preclinical

36. Cancer CD98 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
36.1 Phase-I

37. Cancer CD200 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
37.1 Preclinical
37.2 Clinical
37.3 Phase-II

38. Cancer CD223 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
38.1 Preclinical
38.2 Phase-I
38.3 Phase-I/II
38.4 Phase-II

39. Cancer CD248 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
39.1 Preclinical
39.2 Phase-II

40. Cancer CD274 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
40.1 Research
40.2 Preclinical
40.3 Clinical
40.4 Phase-I
40.5 Phase-I/II

41. Cancer CD319 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
41.1 Phase-I

42. Cancer Multiple Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
42.1 Preclinical
42.2 Phase-I
42.3 Phase-I/II
43. Competitive Landscape
43.1 AryoGen Biopharma
43.2 Biocad
43.3 Biogen Idec
43.4 Celltrion
43.5 Genentech
43.6 Genmab
43.7 GLYCART Biotechnology
43.8 Hetero Drugs
43.9 mAbxience
43.10 MedImmune
43.11 Merck
43.12 Sandoz
43.13 UCB



List of Figures

Figure 1-1: Evolution of CD Antigen Based Therapeutic Antibodies in Cancer Therapy
Figure 2-1: CD Antigens as Markers on Normal Leukocytes
Figure 2-2: Significance of CD Antigen in Cancer Cell & its Inhibition by Therapeutic Antibody
Figure 4-1: Types of CD Antigen Based Cancer Therapeutics
Figure 4-2: Structure of Monoclonal Antibody
Figure 4-3: Types of Therapeutic Monoclonal Antibodies
Figure 4-4: Architecture of Antibody Drug Conjugates
Figure 4-5: Bispecific Antibody Structure
Figure 5-1: Advanced CD Antigen Targeting Cancer Therapies
Figure 5-2: Structure of Radio Immunoconjugate
Figure 5-3: Structure of Bispecific T-Cell Engager Antibody
Figure 5-4: Structure of Dual Affinity Re-Targeting Antibody
Figure 6-1: Mechanism of Action of Anti-CD20 Monoclonal Antibody Rituximab
Figure 6-2: Mechanism of Action of Anti-CD30 Antibody Drug Conjugate Brentuximab Vedotin
Figure 9-1: Global - Cancer Therapeutic Monoclonal Antibody Market Share (%), 2017
Figure 9-2: Global - CD20 Cancer Therapeutic Segmentation by Region (%), 2017
Figure 9-3: Global - Rituximab Sales (US$ Billion), 2013-2016
Figure 9-4: Global - Ofatumumab Sales (US$ Million), 2013-2016
Figure 9-5: Global - Obinutuzumab Sales (US$ Million), 2015 & 2016
Figure 9-6: Global - Ibritumomab Tiuxetan Sales (US$ Million), 2013-2016
Figure 9-7: Global - Daratumumab Sales (US$ Million), 2015-2017*
Figure 9-8: Global - Daratumumab Half Yearly Sales (US$ Million), 2016 & 2017
Figure 9-9: Global - Brentuximab Vedotin Sales (US$ Million), 2014-2017
Figure 9-10: Global - Blinatumomab Sales (US$ Million), 2015-2017*
Figure 9-11: Global - Blinatumomab Sales (US$ Million), 2015-2017
Figure 9-12: Global - Cancer CD Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-13: Global - Cancer CD Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-14: Global - Cancer CD3 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-15: Global - Cancer CD3 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-16: Global - Cancer CD19 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-17: Global - Cancer CD19 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-18: Global - Cancer CD20 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-19: Global - Cancer CD20 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-20: Global - Cancer CD22 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-21: Global - Cancer CD22 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-22: Global - Cancer CD26 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-23: Global - Cancer CD26 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-24: Global - Cancer CD27 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-25: Global - Cancer CD27 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-26: Global - Cancer CD33 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-27: Global - Cancer CD33 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-28: Global - Cancer CD38 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-29: Global - Cancer CD38 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-30: Global - Cancer CD44 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-31: Global - Cancer CD44 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-32: Global - Cancer CD47 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-33: Global - Cancer CD47 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-34: Global - Cancer CD52 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-35: Global - Cancer CD52 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-36: Global - Cancer CD55 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-37: Global - Cancer CD55 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-38: Global - Cancer CD200 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-39: Global - Cancer CD200 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-40: Global - Cancer CD223 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-41: Global - Cancer CD223 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-42: Global - Cancer CD248 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-43: Global - Cancer CD248 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-44: Global - Cancer CD274 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-45: Global - Cancer CD274 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-46: Global - Cancer CD Multiple Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-47: Global - Cancer CD Multiple Antigen Inhibitors Pipeline by Phase (Number), 2017
Figure 9-48: Global - Cancer CD Total Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-49: Global - Cancer CD Total Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 10-1: US - Rituximab Intravenous Solution Price by Concentration (10mg/mL) (US$/Unit), 2017
Figure 10-2: US - Rituximab Vial Price by Quantity (US$), 2017
Figure 10-3: Rituximab Treatment Cost Analysis by Route of Administration (US$), 2017
Figure 10-4: US - Ofatumumab Intravenous Solution Price by Concentration (20mg/mL) (US$/Unit), 2017
Figure 10-5: US - Ofatumumab Vial Price by Quantity (US$), 2017
Figure 10-6: Ofatumumab - Treatment Dosage Analysis (mg)
Figure 10-7: Ofatumumab - Price Analysis by Dosage (US$)
Figure 10-8: Obinutuzumab First Cycle Dosage Analysis (mg)
Figure 10-9: Obinutuzumab Treatment Dosage Analysis (mg)
Figure 10-10: US - Obinituzumab Solution Price (US$), 2017
Figure 10-11: Obinutuzumab - Therapy First Cycle Average Cost (US$), 2017
Figure 10-12: Obinutuzumab Average Treatment Cost (US$), 2017
Figure 10-13: Daratumumab Monotherapy Dosage Analysis (mg)
Figure 10-14: Daratumumab Combination Therapy Dosage Analysis (mg)
Figure 10-15: US - Daratumumab Intravenous Solution Cost by Concentration (20mg/mL) (US$/Unit), 2017
Figure 10-16: Daratumumab Vial Price Analysis by Quantity (US$), 2017
Figure 10-17: Daratumumab Monotherapy Average Cost Analysis (US$), 2017
Figure 10-18: Daratumumab Combination Therapy Average Cost Analysis (US$), 2017
Figure 10-19: US - Brentuximab Vedotin Price Analysis, (US$), 2017
Figure 10-20: US - Brentuximab Vedotin Treatment Expenditure (US$), 2014
Figure 10-21: US - Brentuximab Vedotin Treatment Cost (US$), 2017
Figure 10-22: Global - Gemtuzumab Ozogamicin Treatment Cycle Price Analysis (US$), 2010 & 2017
Figure 10-23: US - Ibritumomab Tiuxetan Product & Dose Price Analysis (US$), 2017
Figure 10-24: US - Blinatumomab Dosage Average Price Analysis (US$), 2017
Figure 10-25: US - Blinatumomab Treatment First Cycle Average Cost (US$), 2017
Figure 10-26: US - Blinatumomab Treatment Subsequent Cycle Average Cost (US$), 2017
Figure 12-1: Global CD Antigen Based Cancer Therapy Market Driving Factors
Figure 12-2: Gemtuzumab vs Best Available Therapy Survival Rate
Figure 12-3: Global CD Antigen Based Cancer Therapeutic Market Challenges

List Of Tables

Table 10-1: Rituximab Dosage Indications for Treatment of Different Cancer Conditions

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-4706799o

Visit at : https://www.kuickresearch.com/page-Pharmaceutical%20and%20Healthcare.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.